AbbVie (NYSE:ABBV) shares traded in the red on Thursday, making it the seventh consecutive day of losses. The stock closed ...

Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

Schizophrenia drug didn't do well in the lab Just before the market open on Monday, AbbVie revealed that its emraclidine ...

And Cerevel Therapeutics, which had positive early testing results for emraclidine, its drug that aims to treat schizophrenia ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Shares of AbbVie have dropped sharply ...